Carter Immunology Center and Department of Microbiology, Immunology, and Cancer Biology, University of Virginia School of Medicine, Charlottesville, Virginia.
Cancer Immunol Res. 2017 Dec;5(12):1062-1073. doi: 10.1158/2326-6066.CIR-17-0190. Epub 2017 Nov 2.
Although CD8 T cells are critical for controlling tumors, how they are recruited and home to primary and metastatic lesions is incompletely understood. We characterized the homing receptor (HR) ligands on tumor vasculature to determine what drives their expression and their role in T-cell entry. The anatomic location of B16-OVA tumors affected the expression of E-selectin, MadCAM-1, and VCAM-1, whereas the HR ligands CXCL9 and ICAM-1 were expressed on the vasculature regardless of location. VCAM-1 and CXCL9 expression was induced by IFNγ-secreting adaptive immune cells. VCAM-1 and CXCL9/10 enabled CD8 T-cell effectors expressing αβ integrin and CXCR3 to enter both subcutaneous and peritoneal tumors, whereas E-selectin enabled E-selectin ligand effectors to enter subcutaneous tumors. However, MadCAM-1 did not mediate αβ effector entry into peritoneal tumors due to an unexpected lack of luminal expression. These data establish the relative importance of certain HRs expressed on activated effectors and certain HR ligands expressed on tumor vasculature in the effective immune control of tumors. .
虽然 CD8 T 细胞对于控制肿瘤至关重要,但它们如何被招募并归巢到原发性和转移性病变部位尚不完全清楚。我们对肿瘤血管上的归巢受体 (HR) 配体进行了特征分析,以确定是什么驱动了它们的表达以及它们在 T 细胞进入中的作用。B16-OVA 肿瘤的解剖位置影响 E-选择素、MadCAM-1 和 VCAM-1 的表达,而无论位置如何,HR 配体 CXCL9 和 ICAM-1 均在血管上表达。VCAM-1 和 CXCL9 的表达是由分泌 IFNγ 的适应性免疫细胞诱导的。VCAM-1 和 CXCL9/10 使表达 αβ 整合素和 CXCR3 的 CD8 T 细胞效应器能够进入皮下和腹膜肿瘤,而 E-选择素使 E-选择素配体效应器能够进入皮下肿瘤。然而,MadCAM-1 由于管腔表达的意外缺失而未能介导 αβ 效应器进入腹膜肿瘤。这些数据确立了在有效免疫控制肿瘤中,激活效应器上表达的某些 HR 以及肿瘤血管上表达的某些 HR 配体的相对重要性。